Hookipa Pharma Stock Price, News & Analysis

HOOKIPA Pharma (NASDAQ: HOOK) announces a clinical collaboration with Merck to assess HB-200 with KEYTRUDA as a first-line treatment for advanced head and neck squamous cell carcinoma. This initiative follows promising results from the ongoing Phase 1/2 trial, where HB-201 showed an 18% overall response rate and a median progression-free survival of 3.45 months. Planned Phase 2 trials are set for 2022, indicating HOOKIPA's commitment to advancing its immunotherapeutic pipeline targeting HPV16-positive cancers.

HOOKIPA Pharma, listed on NASDAQ as HOOK, announced participation in several upcoming virtual investor conferences. Key events include the Morgan Stanley 19th Annual Global Healthcare Conference on September 9-10 and 13-15, featuring a fireside chat on September 10 at 8:45 AM ET. The H.C. Wainwright 23rd Annual Global Investment Conference is scheduled for September 13-15 with a presentation on September 13 at 7:00 AM ET. Additionally, HOOKIPA will present at the 2021 Cantor Virtual Global Healthcare Conference on September 28 from 8:00-8:30 AM ET. Webcasts will be available on their website.

HOOKIPA Pharma reported its Q2 2021 financial results, highlighting progress in its arenaviral immunotherapy programs. HB-200 for HPV16+ cancers showed promising Phase 1 data, with activated CD8+ T cells reaching up to 40% of the T cell pool. Revenue declined to $5.4 million from $6.7 million year-over-year, attributed to a lack of milestone payments from Gilead. The net loss increased to $17.2 million, up from $7.1 million in Q2 2020. Cash reserves decreased to $102.9 million, down from $143.2 million as of the end of 2020, reflecting increased R&D costs.

HOOKIPA Pharma has published promising pre-clinical data on its arenaviral-based immunotherapeutic targeting melanoma in Nature Communications. A single intra-tumoral injection resulted in tumor regression in all tested mice, achieving tumor cures in approximately 60%. The findings demonstrate the ability to modulate the tumor microenvironment and induce significant T cell responses. HOOKIPA’s ongoing Phase 1/2 trials with their HPV programs further explore this novel therapeutic platform, showcasing potential in cancer treatment and addressing unmet medical needs.

HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced it will release its second quarter 2021 financial results on August 12, 2021, before market opening. The company focuses on developing novel immunotherapeutics using its proprietary arenavirus platform, with ongoing clinical trials for HPV 16-positive cancers and Cytomegalovirus. HOOKIPA aims to mobilize T cells and antibodies to combat serious diseases, with additional preclinical research in prostate cancer, HIV, and Hepatitis B in collaboration with Gilead Sciences.

HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced participation in upcoming virtual investor conferences, including the SVB Leerink CybeRx Series on June 21-22 and the JMP Securities Life Sciences Conference on June 16-17, featuring a fireside chat on June 17 at 10:00am ET. The live webcast will be available on HOOKIPA's website, with an archived replay for 30 days. HOOKIPA focuses on developing immunotherapies using its proprietary arenavirus platform, targeting oncology and infectious diseases, with ongoing clinical trials for Human Papilloma Virus and Cytomegalovirus.

HOOKIPA Pharma reported positive Phase 1 data for HB-200, a novel arenaviral therapeutic targeting HPV16+ cancers, at the 2021 ASCO Annual Meeting. The therapy demonstrated an average of 6% to 40% tumor-specific CD8+ T cell responses, supporting its potential efficacy. HB-201 monotherapy achieved an 18% overall response rate and a median progression-free survival of 3.45 months in heavily pretreated patients. The findings suggest that HOOKIPA's arenaviral platform could facilitate new cancer immunotherapy options. Further studies are planned for 2022.

HOOKIPA Pharma announced that the first data from their Phase 1 study on HB-201/HB-202, an arenaviral therapeutic for HPV16+ cancers, will be presented at the ASCO Annual Meeting from June 4-8, 2021. This includes safety, tolerability, and preliminary anti-tumor activity from 40 patients. The presentation highlights the potential of HOOKIPA's novel immunotherapeutics to enhance cancer treatment. Following the presentation, an investor event will provide insights into the trial's findings and HOOKIPA's future plans.

HOOKIPA Pharma reported encouraging preliminary Phase 1 data for its oncology candidates, HB-201 and HB-202, showing a robust antigen-specific CD8+ T cell response following one dose. The results align with prior pre-clinical studies, demonstrating an increase of up to 8% in antigen-specific circulating CD8+ T cells in patients with HPV16+ cancers. Financially, HOOKIPA posted revenues of $5.3 million for Q1 2021, up from $3.7 million in Q1 2020. However, net loss widened to $17.2 million, reflecting increased R&D expenses. The company is set to present further data at ASCO and other upcoming conferences.